UPDATE: The LUMINA-1 Plain Language Summary is now available in Chinese, Dutch, French, Italian, Japanese, Polish, Portuguese and Spanish. 

On September 28, 2023, Regeneron published the results of their Phase 2 LUMINA-1 Clinical Trial of the drug garetosmab in Nature Medicine, a peer-reviewed publication. Regeneron also published clinical pharmacology results from the LUMINA-1 Trial in the Journal of Clinical Pharmacology.

To support the understanding of these results by FOP families, a graphical plain language summary of the results was published in Future Medicine on April 11, 2024. 

"The LUMINA-1 study showed that in people with FOP, garetosmab stopped new heterotopic bone from developing in areas that it should not and also reduced flare-ups. This shows that garetosmab may be a useful treatment for people with FOP. More testing is needed to better understand the benefits and risks of garetosmab."

In November 2022, Regeneron opened OPTIMA, a Phase 3 trial of the drug garetosmab. More information is also available at optimatrial.com

Questions or comments about this publication? Contact us at [email protected]